Cantor Fitzgerald Reiterates Overweight Rating on Acrivon Therapeutics Inc (ACRV)

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Acrivon Therapeutics Inc (NASDAQ: ACRV).

The analyst commented, “Acrivon provided an R&D update on the AP3 platform and data update of ACR-368 (CHK1/2i) and ACR-2316 (WEE1/ PKMYT1i) after close yesterday (3/25). We view the ACR-368 data in endometrial cancer (EC) as solid, despite efficacy dilution from the prior cut. Deprioritizing ovarian and bladder indications means fewer eggs in the basket and a smaller TAM, but we don't think much credit has been given beyond EC. The oppty in EC is clearly more compelling so the prioritization makes sense from a resourcing perspective. The questions we had were on registrational pathway and whether the AA path is viable based on new data.”

For an analyst ratings summary and ratings history on Acrivon Therapeutics Inc click here. For more ratings news on Acrivon Therapeutics Inc click here.

Shares of Acrivon Therapeutics Inc closed at $5.39 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Boeing lands two U.S. defense contracts worth over $711M
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery